MabThera approved for rheumatoid arthritis
July 11, 2006Sales and Marketing
Roche's blockbuster cancer drug MabThera has gained European marketing approval to treat rheumatoid arthritis.First launched in 1997, MabThera (rituximab) made …
Avastin filed for breast cancer treatment
July 10, 2006Sales and Marketing
Roche's Avastin could be licensed to treat advanced breast cancer in Europe by early 2007, following its filing with regulator …
Lilly to close UK manufacturing site but retains R&D operations
July 7, 2006Manufacturing and Production
Pharmaceutical company Lilly is to close its UK manufacturing facility in Basingstoke with as many as 300 employees expected to …
Anti-smoking ad lights up Best of Health awards
July 7, 2006Medical Communications Best of Health, advertising, awards, events
Clear Marketing Communications has taken the top prize at the 2006 Best of Health Awards with a striking advert highlighting …
Work progressing on Scotland’s ‘unique’ biotech campus
July 7, 2006Research and Development
Plans to make Scotland a major centre for innovative biotech and pharmaceutical research are progressing, with a major new centre …
Company behind Northwick Park trial files for insolvency
July 7, 2006Sales and Marketing
The pharmaceutical company behind TGN 1412, the drug which caused near-fatal reactions in six clinical trials volunteers at Northwick Park, …
Practice-based commissioning uptake exaggerated, say GPs
July 7, 2006Doctors' leaders have challenged claims by the government that as many as 40% of GPs are engaged in practice-based commissioning, …
Venomous snail provides Eisai with new painkiller
July 7, 2006Research and Development, Sales and Marketing
Patients suffering severe chronic pain have new hope of relief thanks to a venomous sea snail found off the coast …
Scotland NHS appoints first private provider
July 6, 2006Scotland's health service is set to appoint its first private provider to cut surgery waiting times, following the controversial policy …
CRM and keeping up with your customers
July 6, 2006Sales and Marketing CRM, customer relationship management, sales
Customer relationship management systems are now universally used by major pharmaceutical companies, in fact many have several.Evolving from their beginnings …
Patents: extending the golden years
July 5, 2006Sales and Marketing patents, sales, strategy
Much like death and taxes, one of the certainties of this world is that patents expire, and if a product …
Hepatitis B treatment Baraclude approved in Europe
June 30, 2006Sales and Marketing
A new hepatitis B treatment Baraclude has been approved in Europe and could eventually become a first-line choice thanks to …
Acomplia launched in UK
June 29, 2006Sales and Marketing
Acomplia, the long-awaited weight-loss drug from Sanofi-Aventis has been launched in the UK, and promises to help patients shed pounds …
Generic company fails to overturn Lipitor patent in UK
June 29, 2006Sales and Marketing generics
A legal challenge to overturn Pfizer's UK patent on its top-selling cholesterol treatment has failed.Lipitor is the biggest selling drug …
New COPD standards to tackle inequalities
June 29, 2006Sales and Marketing
New national standards for the treatment of one of the biggest killers in the UK have been launched, with a …
Gene therapy: the tailor-made treatment
June 28, 2006Research and Development drug development, gene therapy
At the risk of boring my audience, I really can't help beginning with yet another attack of nostalgia ,or rather …
Calling up reinforcements
June 28, 2006Business Services interim management, recruitment
In the pharmaceutical industry outsourcing has never enjoyed greater popularity and all the indications are that this trend is set …
New drug for treatment-resistant HIV approved
June 28, 2006Sales and Marketing
Prezista, a new drug for patients who have treatment-resistant HIV, has been approved in the US.The treatment from Johnson & …
Novartis to market new vaccine for Japanese encephalitis
June 28, 2006Sales and Marketing
Novartis has licensed the marketing rights to a phase III vaccine from Intercell for Japanese encephalitis virus infections. The vaccine …
J&J buys Pfizer consumer health division for $16 billion
June 27, 2006Sales and Marketing
Healthcare conglomerate Johnson & Johnson is to buy Pfizer's consumer health division for more than $16 billion, a move which …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
